If you have started investing in March 2020 you need to cautious and invest slowly without getting carried away by recent healthy returns.
BIOCON - Due to higher R&D spend, CAPEX and longer gestation period, the return ratios are currently low. To understand more about BIOLOGICS, read the respective thread. I found this paid session (Rs 200) very informative if you are new to pharma sector. To me, it seems expensive at current price after the resent run so don’t urge to buy. As it is a multi year story, you can consider SIPing or buy at dips.
PS: BIOCON constitutes ~5% of my portfolio, entered at lower price.